Clinical Trial Update: Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib in first-line renal cell carcinoma after progression on immunotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Clear Cell Renal Carcinoma | Phase 2 | Status: COMPLETED